LAVA Therapeutics N.V.

LVTX

NL0015000AG6

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
3.09 ^USD	-0.64%		+1.98%	+95.57%

Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Lava Therapeutics B.V.(NasdaqGS:LVTX) added to NASDAQ Composite Index

March 26, 2021 at 12:00 am EDT

Lava Therapeutics B.V. has been added to NASDAQ Composite Index .

Latest news about LAVA Therapeutics N.V.

LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 20	CI
LAVA Therapeutics N.V. Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052	Mar. 05	CI
Sector Update: Health Care Stocks Softer Late Afternoon	Jan. 25	MT
Sector Update: Health Care Stocks Slipping Thursday Afternoon	Jan. 25	MT
Sector Update: Health Care	Jan. 25	MT
Lava Therapeutics to Study Gammabody Combined With Merck's Keytruda to Treat Metastatic Prostate Cancer	Jan. 25	MT
Upbeat US Economic Growth Data Lift Sentiment, Driving Premarket Gains for US Equity Futures	Jan. 25	MT
Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda	Jan. 25	DJ
Top Premarket Gainers	Jan. 25	MT
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc. to Evaluate LAVA-1207 in Combination with KEYTRUDA	Jan. 25	CI
LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
HC Wainwright Adjusts Price Target on Lava Therapeutics to $6 From $9, Maintains Buy Rating	23-08-23	MT
LAVA Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Lava Therapeutics to Halt LAVA-051 Clinical Trial, Focus on Potential Prostate Cancer Treatment LAVA-1207	23-06-14	MT
LAVA Therapeutics N.V. Provides Updates on Clinical Programs and Extends the Cash Runway	23-06-14	CI
LAVA Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-08	CI
Sector Update: Health Care Stocks Rising Late Friday	23-06-02	MT
Sector Update: Health Care	23-06-02	MT
Top Midday Gainers	23-06-02	MT
Top Premarket Gainers	23-06-02	MT
LAVA Therapeutics Shares Rise Premarket Following Selection by Janssen Biotech to Support Development of Cancer Treatment	23-06-02	MT
North American Morning Briefing : Stock Futures Rise as Jobs Report Swings Into Focus	23-06-02	DJ
Stocks to Watch : Lululemon, Lava Therapeutics, Tilly's, Oncorus	23-06-01	DJ
LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-04-11	CI

LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Citizens JMP Life Sciences Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.869 EUR

Average target price

6.684 EUR

Spread / Average Target

+132.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LAVA THERAPEUTICS N.V.	+95.57%	81.23M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research

LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Biotechnology & Medical Research

Lava Therapeutics B.V.(NasdaqGS:LVTX) added to NASDAQ Composite Index

Latest news about LAVA Therapeutics N.V.

Chart LAVA Therapeutics N.V.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research